Essential thrombocythemia: a retrospective study on the clinical course of 100 patients.
We report a study concerning 100 patients affected by essential thrombocythemia: 90 adult (age greater than 20 years) and 10 pediatric subjects. The diagnosis was made by chance (78%), because of hemorrhages (10%), thrombosis (9%), vasomotor symptoms (29%). In the adult group, single-agent chemotherapy was performed with good remission using pipobroman or interferon. Antiaggregant agents were used in all patients at diagnosis. During the clinical course only a few complications occurred.
Chistolini
A
A
Dipartimento di Biopatologia Umana, Università La Sapienza, Roma, Italy.
Mazzucconi
M G
MG
Ferrari
A
A
la Verde
G
G
Ferrazza
G
G
Dragoni
F
F
Vitale
A
A
Arcieri
R
R
Mandelli
F
F
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002066:Busulfan / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D006474:Hemorrhagic Disorders / Q000209:etiology; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007370:Interferon Type I / Q000627:therapeutic use; D007558:Italy / Q000453:epidemiology; D007938:Leukemia / Q000209:etiology; D008875:Middle Aged; D010885:Pipobroman / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011994:Recombinant Proteins; D012189:Retrospective Studies; D013920:Thrombocythemia, Essential / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology*; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control
D007370:Interferon Type I; D010975:Platelet Aggregation Inhibitors; D011994:Recombinant Proteins; D010885:Pipobroman; D002066:Busulfan; D006918:Hydroxyurea